+ +

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of HRPT2/CDC73 expression in 293T cell lysate.    

  
  

The HRPT2 gene, also known as CDC73. encodes the protein parafibromin, a tumor suppressor implicated in cell cycle regulation and transcriptional modulation through its interaction with the PAF1 complex. Germline mutations in HRPT2 are linked to hyperparathyroidism-jaw tumor (HPT-JT) syndrome, an autosomal dominant disorder characterized by parathyroid adenomas/carcinomas, ossifying jaw tumors, and renal lesions. Somatic HRPT2 mutations are also observed in sporadic parathyroid carcinomas and a subset of renal and thyroid tumors.

Antibodies targeting the HRPT2/CDC73 gene product (parafibromin) are primarily utilized in research and diagnostics to assess protein expression levels. Loss of nuclear parafibromin expression, detected via immunohistochemistry (IHC), serves as a biomarker for HRPT2 inactivation, aiding in the distinction of parathyroid carcinoma from benign adenomas. These antibodies have also facilitated studies exploring parafibromin's role in Wnt/β-catenin signaling, histone modification, and cell proliferation.

Clinically, HRPT2/CDC73 antibody testing supports the diagnosis of HPT-JT syndrome and guides surveillance in high-risk individuals. However, interpretation requires caution, as aberrant staining patterns may arise from technical variability or non-inactivating mutations. Ongoing research aims to refine its utility in prognostication and targeted therapies for HRPT2-deficient tumors.